Top Line results from Phase 2 study in pancreatic cancer (With MDACC) - 1H 2019 Technical overview - above MA20
Breakdown will short tomorrow will see if bounce as possible play, see shorting early morning then bouncing to match initial high, good possibility considering multi day runner.
BLRX had a strong rally today and it's just getting started. In the related idea my price target was $1.34. Today's high was $1.78 Check out the weekly chart: Photo Finish. $1.34 was 1.618 extension level from Waves 1 & 2. Since the price-action broke $1.34 we will have an extended 3rd wave. I expect a very strong rally tomorrow, I will update in the...
BLRX is in the middle of an extending 3rd wave. Target is $1.34. If BLRX crosses $1.34 which is likely I will hold and reassess the trade. -AB
FYI: BLRX is getting ready for a major breakout. See related BLRX ideas for further analysis. Weekly: Daily:
BLRX is about to breakout. 6HR Chart Daily: Elliot Waves: Breakout should be imminent...
BLRX chart is looking pretty prone for a breakout. BLRX has been undergoing consolidation and it appears to be ready to go higher Technical Analysis: BB and Keltner Channel Squeeze Price and Volume Trend during consolidation Positive Volume Index Regression Slope Rate of Change Money Flow Small Wave Count Overall Chart (Weekly) Overall...
BLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as ...